The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder
NCT ID: NCT00044187
Last Updated: 2006-07-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
130 participants
INTERVENTIONAL
2001-04-30
2003-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The purposes of this study are to determine the safety of olanzapine when given in combination with the Anti-obesity Agent and any side effects that might be associated with it and whether weight-gain agent can help treat weight gain that may be associated with taking olanzapine.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Sibutramine
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Exclusion Criteria
* You have taken remoxipride within the past 6 months.
* You are allergic to olanzapine or Anti-obesity Agent.
* You have uncontrolled high blood pressure, congestive heart failure, or have had a stroke.
* You have a serious medical illness, such as heart, liver, or kidney disease.
* You are pregnant or breast feeding.
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eli Lilly and Company
INDUSTRY
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
El Centro, California, United States
Jacksonville, Florida, United States
Miami, Florida, United States
Boise, Idaho, United States
Chicago, Illinois, United States
Indianapolis, Indiana, United States
Lafayette, Indiana, United States
Prairie Village, Kansas, United States
Milford, Massachusetts, United States
Clementon, New Jersey, United States
Beachwood, Ohio, United States
Johnson City, Tennessee, United States
Memphis, Tennessee, United States
Houston, Texas, United States
Richmond, Virginia, United States
Bellevue, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
F1D-MC-HGJJ
Identifier Type: -
Identifier Source: secondary_id
5102
Identifier Type: -
Identifier Source: org_study_id